A US jury has found that Takeda engaged in an antitrust scheme to delay a generic version of a constipation drug, according to a Reuters report on the verdict.

The decision comes from a federal jury, which sided with plaintiffs who accused the Japanese pharmaceutical company of using improper means to hold off generic competition. The jury's finding centers on conduct intended to postpone the market entry of a lower-cost generic substitute for Takeda's constipation medication.

The verdict adds Takeda to the list of major pharmaceutical manufacturers that US juries have held liable for so-called "pay-for-delay" or similar exclusionary conduct. Such cases typically arise when brand-name drugmakers are accused of striking arrangements or pursuing tactics that keep generics off the market beyond the life of lawful patent protection.

For practitioners, the decision is a reminder that pharmaceutical antitrust exposure in the United States continues to generate substantial jury verdicts. Companies facing patent-settlement or product-lifecycle litigation should expect plaintiffs to pursue damages theories built on delayed generic entry, and defense counsel should prepare for juries willing to characterize aggressive lifecycle management as unlawful exclusionary conduct.

The practical consequence of the jury's finding will be shaped by subsequent proceedings, including any damages phase, post-trial motions, and potential appeals. Takeda may seek to overturn the verdict or limit its financial exposure through these channels.

The case is part of a broader pattern of US antitrust enforcement and private litigation concerning generic drug delays, an area that has drawn sustained attention from regulators, Congress, and the courts for more than a decade.

Reuters reported the jury's finding. Further details on the amount of any damages award, the specific claims decided, and the court in which the verdict was returned were not included in the initial report.